Amplia Appoints Nucleus Network to Conduct Phase 1 Clinical Trial

What's happened?

Amplia Therapeutics Limited (ASX: ATX) has appointed the Nucleus Network in Melbourne to conduct its upcoming Phase 1 clinical trial testing AMP945, the Company’s proprietary Focal Adhesion Kinase inhibitor (FAKi).

What are the key highlights?

1. The Phase-1 trial will enrol up to 64 healthy volunteers and aims to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AMP945 when given as single and multiple doses.
2. By conducting the trial in healthy volunteers, data from the trial may be used to support Phase 2 clinical trials for multiple diseases including various solid cancers and fibrotic diseases such as idiopathic pulmonary fibrosis.
3. The company expects data from the Phase 1 trial to be available in the first half of 2021.

For further information, please refer to the announcement linked below.